Abstract | BACKGROUND: An unexpectedly high seroprevalence and pathogenic potential of human parvovirus B19 (B19V) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (CQ) as first-line treatment for malaria. The aims of this study were to assess the effect of CQ and other common antimalarial drugs on B19V infection in vitro and the possible epidemiological consequences for children from Papua New Guinea (PNG). METHODOLOGY/PRINCIPAL FINDINGS: CONCLUSIONS/SIGNIFICANCE: Our data strongly suggest that 4-aminoquinoline drugs and their metabolites exacerbate B19V-associated anemia by promoting B19V replication. Consideration should be given for choosing a non-4-aminoquinoline drug to partner artemisinin compounds in combination antimalarial therapy.
|
Authors | Claudia Bönsch, Christoph Kempf, Ivo Mueller, Laurens Manning, Moses Laman, Timothy M E Davis, Carlos Ros |
Journal | PLoS neglected tropical diseases
(PLoS Negl Trop Dis)
Vol. 4
Issue 4
Pg. e669
(Apr 27 2010)
ISSN: 1935-2735 [Electronic] United States |
PMID | 20436917
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimalarials
- DNA, Viral
- Intercellular Signaling Peptides and Proteins
- RNA, Viral
- Chloroquine
|
Topics |
- Animals
- Antimalarials
(adverse effects)
- Case-Control Studies
- Cell Line
- Child
- Child, Preschool
- Chloroquine
(adverse effects, pharmacology)
- DNA, Viral
(biosynthesis)
- Female
- Humans
- Infant
- Intercellular Signaling Peptides and Proteins
(pharmacology)
- Male
- Papua New Guinea
- Parvoviridae Infections
(virology)
- Parvovirus B19, Human
(drug effects, growth & development)
- RNA, Viral
(biosynthesis)
- Virus Replication
(drug effects)
|